MapLight dives despite positive data for schizophrenia drug

Data ReadoutpositiveMapLight schizophrenia drugCobenfyNegative

AI Analysis

Summary

MapLight announced positive data for its schizophrenia drug candidate, but shares fell over 66% as investors deemed the data non-competitive with Bristol Myers' approved Cobenfy.

Outcome Details

Positive data for schizophrenia drug, but market viewed as not competitive with Bristol Myers' Cobenfy

Importance:4/10

Sentiment:

-0.70

schizophreniaclinical datacompetitive pressurestock decline

Related Companies

$BMY $CELG-RI

Read the original article

Published by BioPharma Dive on July 27, 2026 4:12 PM

Read Original